Immunotherapy Toxicity - 03/03/19
Résumé |
The development of immunotherapy to target cancer has led to improved treatment of many types of malignancy. The immune checkpoint inhibitors are a class of medications that block cell signaling and allow the immune system to recognize and attack cancer cells. CTLA-4, PD-1, and PD-L1 inhibitors have been approved as treatment options in many different types of localized and advanced malignancies. Immune checkpoint inhibitors can be associated with unique side effects known as immune-related adverse events. Side effects most commonly occur in the skin, gastrointestinal tract, lung, and endocrine glands but can affect other organ systems as well.
Le texte complet de cet article est disponible en PDF.Keywords : Immunotherapy, Toxicity, Immune checkpoint inhibitors, Immune-related adverse events
Plan
| Disclosure Statement: C.M. Mantia has nothing to disclose; E.I. Buchbinder receives clinical trial support from BMS, Merck, Novartis, Lilly, and Checkmate and consulting payments from BMS, Checkmate. |
Vol 33 - N° 2
P. 275-290 - avril 2019 Retour au numéro
Article précédent
- Cytokine Therapy
- Ann W. Silk, Kim Margolin
- Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
- Emanuelle M. Rizk, Robyn D. Gartrell, Luke W. Barker, Camden L. Esancy, Grace G. Finkel, Darius D. Bordbar, Yvonne M. Saenger
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?